Search Within
Applied Filters:
キーワード:'O1139'
Showing 1-8 of 8 結果 for "

O1139

" within 文献
Munehisa Shimamura et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(22), 8191-8196 (2014-05-23)
Osteoprotegerin (OPG) is a soluble secreted protein and a decoy receptor, which inhibits a receptor activator of nuclear factor κB (NF-κB) ligand (RANKL)/the receptor activator of NF-κB (RANK) signaling. Recent clinical studies have shown that a high-serum-OPG level is associated...
Sandra M Sacco et al.
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 39(7), 801-810 (2014-05-23)
Our previous research showed greatest protection to vertebral bone mineral density and strength in ovariectomized (OVX) rats when lignan- and α-linolenic acid-rich flaxseed (FS) is combined with low-dose estrogen therapy (LD) compared with either treatment alone. This study determined the...
W C Dougall et al.
Genes & development, 13(18), 2412-2424 (1999-09-29)
The physiological role of the TNF receptor (TNFR) family member, RANK, was investigated by generating RANK-deficient mice. RANK(-/-) mice were characterized by profound osteopetrosis resulting from an apparent block in osteoclast differentiation. RANK expression was not required for the commitment...
Yang Liu et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 45(5), 1759-1771 (2018-03-02)
Bone morphogenetic proteins (BMPs) and BMP receptors widely participate in osteolytic metastasis of breast cancer, while their role in tumor-stromal interaction is largely unknown. In this study, we investigated whether BMP receptor type 1a (BMPR1a) can alter the interaction between...
Brendan F Boyce et al.
Current osteoporosis reports, 5(3), 98-104 (2007-10-11)
Understanding of osteoclast formation and activation has advanced considerably since the discovery of the RANKL/RANK/OPG system in the mid 1990s. Osteoblasts and stromal stem cells express receptor activator of NF-jB ligand (RANKL), which binds to its receptor, RANK, on the...
Anne-Priscille Trouvin et al.
Clinical interventions in aging, 5, 345-354 (2011-01-14)
Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway...
I Silva et al.
Acta reumatologica portuguesa, 36(3), 209-218 (2011-11-25)
The discovery of the receptor activator of nuclear factor-kB (RANK)/RANK Ligand (RANKL)/osteoprotegerin (OPG) pathway contributed to the understanding of how bone formation and resorption were processed and regulated. RANKL and OPG are members of the tumor necrosis factor (TNF) and...
Joel Jules et al.
Expert opinion on therapeutic targets, 14(9), 923-934 (2010-08-04)
Osteoporosis has become a worldwide health and social issue due to an aging population. Four major antiresorptive drugs (agents capable of inhibiting osteoclast formation and/or function) are currently available on the market: estrogen, selective estrogen receptor modulators (SERMs), bisphosphonates and...
ページ 1 の 1
ページ 1 の 1